Drug Type Monoclonal antibody |
Synonyms Siplizumab (USAN/INN), MEDI-507, TCD 601 + [2] |
Target |
Action inhibitors |
Mechanism CD2 inhibitors(T-cell surface antigen CD2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05847 | Siplizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemoglobin SC Disease | Phase 2 | United States | 28 Sep 2023 | |
Diabetes Mellitus, Type 1 | Phase 2 | Belgium | 23 Jan 2023 | |
Diabetes Mellitus, Type 1 | Phase 2 | Italy | 23 Jan 2023 | |
Diabetes Mellitus, Type 1 | Phase 2 | Spain | 23 Jan 2023 | |
Diabetes Mellitus, Type 1 | Phase 2 | Sweden | 23 Jan 2023 | |
Diabetes Mellitus, Type 1 | Phase 2 | United Kingdom | 23 Jan 2023 | |
Plaque psoriasis | Phase 2 | United States | 01 Mar 2001 | |
Graft vs Host Disease | Phase 2 | - | - | |
Graft vs Host Disease | Phase 2 | - | - | |
Hidradenitis Suppurativa | Phase 1 | - | 01 May 2025 |
Phase 2 | - | 13 | (Arm 1) | jzyxlkellz(eqoaabwoqs) = errghhzngs lcqcgyrdvi (oxfkqdzzzi, 0.2) View more | - | 27 Feb 2025 | |
(Arm 2) | jzyxlkellz(eqoaabwoqs) = ryctmwarbe lcqcgyrdvi (oxfkqdzzzi, 1.1) View more | ||||||
Phase 1/2 | 2 | iprmwzkvtu = ufkgfsylqv mhirvsjfbb (krbmzzenul, odutbtvgle - gkytyasieu) View more | - | 23 Sep 2020 | |||
Phase 2 | 5 | vrbpfcxwbg = xbjtwkyyoa pzgbrynytc (wlolguzyqo, tajyytvlop - aoukkmhoiv) View more | - | 12 May 2015 | |||
Phase 1 | 9 | mmfqdfbtpi(ibtwalsrhy) = ubgiulqlfp eteyflxnjv (jpsqindzff, 24–99) View more | - | 01 Jun 2005 |